Kevin Haworth

Company: Zymeworks

Job title: Pharmacology Scientist

Seminars:

Engineering IL-12 for tumor specific cytotoxicity results in enhanced therapeutic window 3:00 pm

Multiple attenuating components help to mask IL-12 off-tumor mediated cytotoxicity Tumor specific activation of IL12-Fc elicits a potent anti-tumor activity in xenograft models No dose limiting toxicity observed in cynomolgus monkeys at levels well above expected therapeutic dosesRead more

day: Day Two